Please login (Members) to view content or
(Nonmembers) this article.
No votes yet
Oncology Essentials

Controlling Malglycemia in Patients Undergoing Treatment for Cancer

Susan Storey
Veronica J. Brady
Ashley Leak Bryant
Ellen D. Davis
Marilyn J. Hammer
Denise Soltow Hershey
Jill Olausson
Jane Jeffrie Seley
CJON 2016, 20(1), 92-94 DOI: 10.1188/16.CJON.92-94

Patients with or without preexisting diabetes undergoing treatment for cancer may be at risk for malglycemic events. Malglycemia, particularly hyperglycemia and diabetes in patients with cancer, may lead to adverse outcomes. Prevention, prompt recognition, and early intervention to regulate malglycemia can optimize the effects of cancer treatment, minimize the harmful consequences, and improve quality of life for patients with cancer. The development of evidence-based standards of care and protocols are needed to guide clinical practice when caring for patients with cancer.

At a Glance

  • Malglycemia has been associated with increased risk for adverse patient outcomes.
  • Multiple known and unknown factors contribute to the onset of malglycemia.
  • Formal guidelines or protocols are needed to best manage malglycemia in patients receiving cancer treatment.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or